semaglutide
is approved for both diabetes & obesity treatments in adults and children.
Semaglutide is the most well-known GLP-1 agonist as it is sold with the brand names of Ozempic and Wegovy. Ozempic was originally approved for type-2 diabetes and Wegovy was approved for obesity treatment; but they are both the exact same drug with different dosing regimens. Studies consistantly show most people lose an average of 15% of body weight over 63 weeks.
The drugs work by increasing satiety (making people feel full sooner) and suppressing the appetite so they do not feel as hungry. They also improve glycemic control and reduce blood sugar levels. They are one of the most effective treatments available in the battle against obesity and the health problems and early deaths associated with obesity.
The STEP (Semaglutide Treatment Effect in People with Obesity) trials consistantly showed a 15% reduction in weight over 68 weeks.
Another study, Major Adverse Cardiovascular Events (MACE), found that semaglutide significantly reduced the risk of cardivascular (CVD) events such as heart attacks, strokes, and other CVD-related deaths.